Louisiana State Employees Retirement System Makes New Investment in Haemonetics Co. (NYSE:HAE)

Louisiana State Employees Retirement System acquired a new position in Haemonetics Co. (NYSE:HAE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 14,300 shares of the medical instruments supplier’s stock, valued at approximately $1,223,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Haemonetics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock worth $1,956,000 after purchasing an additional 838 shares during the last quarter. ABLE Financial Group LLC boosted its position in Haemonetics by 28.4% in the fourth quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock worth $620,000 after purchasing an additional 1,606 shares during the last quarter. LVZ Inc. boosted its position in Haemonetics by 9.4% in the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock worth $257,000 after purchasing an additional 259 shares during the last quarter. Pacer Advisors Inc. boosted its position in Haemonetics by 64.8% in the fourth quarter. Pacer Advisors Inc. now owns 9,098 shares of the medical instruments supplier’s stock worth $778,000 after purchasing an additional 3,579 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Haemonetics in the fourth quarter worth $345,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 2.9 %

Shares of NYSE HAE opened at $83.61 on Tuesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. Haemonetics Co. has a one year low of $70.74 and a one year high of $95.26. The stock has a market capitalization of $4.25 billion, a PE ratio of 33.99, a P/E/G ratio of 1.92 and a beta of 0.36. The business’s fifty day moving average price is $79.15 and its 200-day moving average price is $82.65.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. During the same period in the previous year, the company posted $0.85 EPS. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Co. will post 3.95 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on HAE. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a research report on Friday, April 12th.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.